In this population, Rasilez HCT 150 mg/ 12.5 mg to 300 mg/ 25 mg provided dose-dependent systolic/ diastolic blood pressure reduction from 20.6/ 12.4 mmHg to 24.8/ 14.5 mmHg, which were significantly superior to the respective monotherapies.